Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Panitumumab Use in Metastatic Colorectal Cancer and Patterns of KRAS Testing: Results from a Europe-Wide Physician Survey and Medical Records Review.
Trojan J, Mineur L, Tomášek J, Rouleau E, Fabian P, de Maglio G, García-Alfonso P, Aprile G, Taylor A, Kafatos G, Downey G, Terwey JH, van Krieken JH. Trojan J, et al. PLoS One. 2015 Oct 22;10(10):e0140717. doi: 10.1371/journal.pone.0140717. eCollection 2015. PLoS One. 2015. PMID: 26491871 Free PMC article.
Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.
Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. Kubicka S, et al. Ann Oncol. 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12. Ann Oncol. 2013. PMID: 23852309 Free article. Clinical Trial.
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
García-Alfonso P, García-Foncillas J, Salazar R, Pérez-Segura P, García-Carbonero R, Musulén-Palet E, Cuatrecasas M, Landolfi S, Ramón Y Cajal S, Navarro S; Spanish Society of Pathology; Spanish Society of Medical Oncology. García-Alfonso P, et al. Clin Transl Oncol. 2015 Apr;17(4):264-73. doi: 10.1007/s12094-014-1252-0. Epub 2014 Nov 6. Clin Transl Oncol. 2015. PMID: 25373533
Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R, Van Cutsem E, Yoshino T, Bodoky G, Prausová J, Garcia-Carbonero R, Ciuleanu T, Garcia Alfonso P, Portnoy D, Cohn A, Yamazaki K, Clingan P, Lonardi S, Kim TW, Yang L, Nasroulah F, Tabernero J. Obermannová R, et al. Ann Oncol. 2016 Nov;27(11):2082-2090. doi: 10.1093/annonc/mdw402. Epub 2016 Aug 29. Ann Oncol. 2016. PMID: 27573561 Free PMC article. Clinical Trial.
Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.
Han van Krieken J, Kafatos G, Bennett J, Mineur L, Tomášek J, Rouleau E, Fabian P, De Maglio G, García-Alfonso P, Aprile G, Parkar P, Downey G, Demonty G, Trojan J. Han van Krieken J, et al. BMC Cancer. 2017 Nov 28;17(1):798. doi: 10.1186/s12885-017-3740-4. BMC Cancer. 2017. PMID: 29183279 Free PMC article. Review.
Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
Fogelman D, Cubillo A, García-Alfonso P, Mirón MLL, Nemunaitis J, Flora D, Borg C, Mineur L, Vieitez JM, Cohn A, Saylors G, Assad A, Switzky J, Zhou L, Bendell J. Fogelman D, et al. Cancer Med. 2018 Nov;7(11):5382-5393. doi: 10.1002/cam4.1703. Epub 2018 Aug 19. Cancer Med. 2018. PMID: 30123970 Free PMC article. Clinical Trial.
Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status.
Ortega Morán L, García Alfonso P, Aguilar Caballero I, Morón García B, Tirado Anula V, de Toro Carmena M, Soto Alsar J, Gutiérrez Alonso N, Bringas Beranek M, Martín Jiménez M, Muñoz Martín AJ. Ortega Morán L, et al. Clin Transl Oncol. 2020 Nov;22(11):2026-2031. doi: 10.1007/s12094-020-02339-1. Epub 2020 Apr 8. Clin Transl Oncol. 2020. PMID: 32270416
164 results